Novavax Announces Positive Results from First Study of Influenza Vaccine and COVID-19 Vaccine Candidate Administered Simultaneously
Watch Novavax's latest callNovavax (NASDAQ:NVAX) Q2 2026 Earnings Call · Replay · Aug 6Read the transcript of Novavax (NASDAQ:NVAX) Q2 2026 Earnings CallStory so far
Earlier from Novavax
- Novavax Announces Positive Data from Three Complementary Studies of COVID-19 Beta (B.1.351) Variant Strain Vaccine
- Novavax Announces Memorandum of Understanding to Explore Expansion of COVID-19 Vaccine Activities in South Korea
- Novavax Reports First Quarter 2021 Financial Results and Operational Highlights
- Novavax and Gavi Execute Advance Purchase Agreement for COVID-19 Vaccine for COVAX Facility
- Novavax Initiates Pediatric Expansion for Phase 3 Clinical Trial of COVID-19 Vaccine
Later from Novavax
- Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
- Novavax Reports Second Quarter 2021 Financial Results and Operational Highlights
- Novavax Appoints Biopharmaceutical Veterans Jim Kelly as Chief Financial Officer and Nasir Egal, Ph.D., as Senior Vice President of Quality Assurance
- Novavax to Participate in OCTAVE-DUO Study to Evaluate Third Dose of Vaccine in Participants with Impaired Immune Systems
- Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants
Follow Novavax into a list and get an email when it puts out news.
Follow Novavax